Cell cycle control, checkpoint mechanisms, and genotoxic stress

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 1, 1999, Pages 5-24

  Shackelford, Rodney E ^a   Kaufmann, William K ^b   Paules, Richard S ^a,b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Ataxia telangiectasia; Cancer; Carcinogens; Cdk; Cell cycle; Checkpoints; Cyclins; DNA repair; Genotoxic stress; Ionizing radiation; Oxidative damage; p53; pRb; UV

Indexed keywords

BENZO[A]PYRENE; CYCLINE; DOUBLE STRANDED DNA; GENE PRODUCT; PROTEIN KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ATAXIA TELANGIECTASIA; CANCER; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DNA REPLICATION; DNA STRAND BREAKAGE; GENE MUTATION; GENOTOXICITY; IONIZING RADIATION; MAMMAL CELL; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPINDLE CELL; ULTRAVIOLET RADIATION;

ATAXIA; ATAXIA TELANGIECTASIA; MAMMALIA;

EID: 0032961422     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s15     Document Type: Review

References (490)

1. Magner LN. A History of Medicine. New York:Marcel Dekker, 1992.
2. Ford JB. The earliest views. Sci Am 278:50-53 (1998).
3. Baserga R. The Biology of Cell Reproduction. Cambridge, MA:Harvard University Press, 1985.
4. Howard A, Pelc SR. Synthesis of nucleoprotein in bean root cells. Nature 167:599-600 (1951).
5. Howard A, Pelc SR. Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity 6:261-273 (1953).
6. Pardee AB, Dubrow R, Hamlin JL, Kletzien RF. Animal cell cycle. Annu Rev Biochem 47:715-750 (1978).
7. Baserga R. Growth in size and cell DNA replication. Exp Cell Res 151:1-5 (1984).
8. Murray A, Hunt T. The Cell Cycle: An Introduction. New York:W.H. Freeman and Co., 1993.
9. Nasmyth K. Viewpoint: Putting the cell cycle in order. Science 274:1643-1645 (1996).
10. Rao PN, Johnson RT. Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature 225:159-164 (1970).
11. Johnson RT, Rao PN. Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. Nature 226:717-722 (1970).
12. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 246:629-633 (1989).
13. Kastan MB, ed. Checkpoint Controls and Cancer. Plainview, NY:Cold Spring Harbor Laboratory Press, 1997.
14. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17:471-480 (1995).
15. Morgan DO. Principles of CDK regulation. Nature 374:131-134 (1995).
16. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol 24:602-615 (1997).
17. 1 phase of the cell cycle. Cell 65:701-713 (1991).
18. 1 events and regulation of cell proliferation. Science 246:603-608 (1989).
19. Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res 1:9-19 (1995).
20. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453-456 (1991).
21. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-Type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-2076 (1994).
22. 1 phase in primary human T lymphocytes. J Biol Chem 268: 4113-4119 (1993).
23. Won K-A, Xiong Y, Beach D, Gilman MZ. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 89:9910-9914 (1992).
24. Cocks BG, Vairo G, Bodrug SE, Hamilton JA. Suppression of growth factor-induced CYL1 cyclin gene expression by antiproliferative agents. J Biol Chem 267:12307-12310 (1992).
25. 1 Cold Spring Harbor Symp Quant Biol 56:69-74 (1991).
26. 1. Genes Dev 7:812-821 (1993).
27. 1 phase in rodent fibroblasts. Genes Dev 7:1559-1571 (1993).
28. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bc/1-linked candidate oncogene. Nature 350:512-515 (1991).
29. Seto M, Yamamoto K, Lida S, Akao Y, Utsumi KR, Kubonishi I, Miyoshi I, Ohtsuki T, Yawata Y, Namba M, et al. Gene rearrangement and over-expression of PRAD1 in lymphoid malignancy with t(11;14)-(q13;q32) translocation. Oncogene 7:1401-1406 (1992).
30. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444 (1991).
31. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679 (1994).
32. 1 phase progression: cycling on cue. Cell 79:551-555 (1994).
33. Kiyokawa H, Busquets X, Powell CT, Ngo L, Rifkind RA, Marks PA. Cloning of a D-type cyclin from murine erythroleukemia cells. Proc Natl Acad Sci USA 89:2444-2447 (1992).
34. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem 267:20412-20415 (1992).
35. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9:2364-2372 (1995).
36. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384:470-474 (1996).
37. Peters G. The D-type cyclins and their role in tumorigenesis. J Cell Sci:89-96 (1994).
38. 1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077-2086 (1994).
39. 1 cyclins. Cell 71:323-334 (1992).
40. Xiong Y, Zhang H, Beach D. D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514 (1992).
41. 1 progression. Oncogene 9:2663-2674 (1994).
42. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582 (1994).
43. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535-5541 (1993).
44. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324 (1994).
45. 1. J Cell Biol 125:625-638 (1994).
46. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 246:581-601 (1997).
47. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429 (1992).
48. 1/S phase. Proc Natl Acad Sci USA 88:1157-1161 (1991).
49. Pearson BE, Nasheuer HP, Wang TS. Human DNA polymerase α gene: sequences controlling expression in cycling and serum-stimulated cells. Mol Cell Biol 11:2081-2095 (1991).
50. 1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J Biol Chem 269:1306-1313 (1994).
51. Furukawa Y, Terui Y, Sakoe K, Ohta M, Saito M. The role of cellular transcription factor E2F in the regulation of cdc2 mRNA expression and cell cycle control of human hematopoietic cells. J Biol Chem 269:26249-26258 (1994).
52. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8:1514-1525 (1994).
53. Lee HH, Chiang WH, Chiang SH, Liu YC, Hwang J, Ng SY. Regulation of cyclin D1, DNA topoisomerase I, and proliferating cell nuclear antigen promoters during the cell cycle. Gene Expr 4:95-109 (1995).
54. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92:12146-12150 (1995).
55. Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J, Helin K, Jansen-Durr P, Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci USA 92:11264-11268 (1995).
56. Tommasi S, Pfeifer GP. In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Mol Cell Biol 15:6901-6913 (1995).
57. Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M, Hatzigeorgiou A, Jansen-Durr P. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 16:3401-3409 (1996).
58. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173-1180 (1996).
59. Oswald F, Dobner T, Lipp M. The E2F transcription factor activates a replication-dependent human H2A gene in early S phase of the cell cycle. Mol Cell Biol 16:1889-1895 (1996).
60. Slansky JE, Farnham PJ. Transcriptional regulation of the dihydrofolate reductase gene. Bioessays 18:55-62 (1996).
61. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262 (1998).
62. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66:1217-1228 (1991).
63. 1 phase of the human cell cycle. Science 257:1689-1694 (1992).
64. 1 cyclin (Cln) function in yeast. Cell 66:1197-1206 (1991).
65. 1-S phase protein kinase. Science 257:1958-1961 (1992).
66. 1-to-S phase transition. Mol Cell Biol 15:2612-2624 (1995).
67. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J, Draetta G. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 121:101-111 (1993).
68. 1-to-S transition in mammalian cells. Oncogene 8:1593-1602 (1993).
69. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 3:171-191 (1997).
70. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753-761 (1998).
71. Kip1. Mol Cell Biol 15:4347-4352 (1995).
72. Minshull J, Golsteyn R, Hill CS, Hunt T. The A-and B-type cyclin associated cdc2 kinases in Xenopus turn on and off at different times in the cell cycle. EMBO J 9:2865-2875 (1990).
73. Pines J, Hunter T. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature (Lond) 346:760-763 (1990).
74. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67:1169-1179 (1991).
75. Lehner CF, O'Farrell PH. The roles of Drosophila cyclins A and B in mitotic control. Cell 61:535-547 (1990).
76. Walker DH, Maller JL. Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354:314-317 (1991).
77. 2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA 89:2824-2828 (1992).
78. 2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell 66:731-742 (1991).
79. Th'ng JP, Wright PS, Hamaguchi J, Lee MG, Norbury CJ, Nurse P, Bradbury EM. The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 63:313-324 (1990).
80. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 11:961-971 (1992).
81. Peeper DS, Parker LL, Ewen ME, Toebes M, Hall FL, Xu M, Zantema A, Van der Eb AJ, Piwnica-Worms H. A-Type and B-type cyclins differentially modulate substrate specificity of cyclin-Cdk complexes. EMBO J 12:1947-1954 (1993).
82. 1/S transition and S-phase progression. Genes Dev 12:2278-2292 (1998).
83. Philips A, Huet X, Plet A, Le Cam L, Vie A, Blanchard JM. The retinoblastoma protein is essential for cyclin A repression in quiescent cells. Oncogens 16:1373-1381 (1998).
84. Dalton S. Cell cycle regulation of the human cdc2 gene. EMBO J 11:1797-1804 (1992).
85. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD, Huang TS. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58:985-990 (1998).
86. Lee M, Nurse P. Cell cycle control genes in fission yeast and mammalian cells. Trends Genet 4:287-290 (1988).
87. Lohka MJ, Hayes MK, Maller JL. Purification of maturation-promoting factor, an intracellular regulator of early mitotic events. Proc Natl Acad Sci USA 85:3009-3013 (1988).
88. +. Cell 54:433-439 (1988).
89. Arion D, Meijer L, Brizuela L, Beach D. cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. Cell 55:371-378 (1988).
90. Dunphy WG, Brizuela L, Beach D, Newport J. The Xenopus cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell 54:423-431 (1988).
91. Labbe JC, Capony JP, Caput D, Cavadore JC, Derancourt J, Kaghad M, Lelias JM, Picard A, Doree M. MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B EMBO J 8:3053-3058 (1989).
92. Gautier J, Minshull J, Lohka M, Glotzer M, Hunt T, Maller JL. Cyclin is a component of maturation-promoting factor from Xenopus. Cell 60:487-494 (1990).
93. cdc2. Cell 58:833-846 (1989).
94. Pines J, Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 115:1-17 (1991).
95. Gallant P, Nigg EA. Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells. J Cell Biol 117:213-224 (1992).
96. Gallant P, Nigg EA. Identification of a novel vertebrate cyclin: cyclin-B3 shares properties with both A-and B-type cyclins. EMBO J 13:595-605 (1994).
97. Jackman M, Firth M, Pines J. Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J 14:1646-1654 (1995).
98. cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes. EMBO J 11:1763-1772 (1992).
99. Pines J, Hunter T. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. EMBO J 13:3772-3781 (1994).
100. Li J, Meyer AN, Donoghue DJ. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc Natl Acad Sci USA 94:502-507 (1997).
101. Erikson E, Maller JL. Biochemical characterization of the p34cdc2 protein kinase component of purified maturation-promoting factor from Xenopus eggs. J Biol Chem 264:19577-19582 (1989).
102. Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs MA, Kirk J, Gannon J, Hunt T. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl Acad Sci USA 95:4344-4349 (1998).
103. 1 cyclin-dependent kinases. Genes Dev 9:1149-1163 (1995).
104. Draetta G. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem Sci 15:378-383 (1990).
105. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 61:441-470 (1993).
106. Morgan DO. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291 (1997).
107. Nigg EA. Cyclin-dependent kinase 7: at the crossroads of transcription, DNA repair and cell cycle control? Curr Opin Cell Biol 8:312-317 (1996).
108. Draetta GF. Cell cycle: Will the real Cdk-activating kinase please stand up? Curr Biol 7:50-52 (1997)
109. 2+ protein kinase regulates entry into mitosis. Nature 342:39-45 (1989).
110. cdc2 protein kinase in vertebrates. EMBO J 10:3321-3329 (1991).
111. cdc2 exclusively on Tyr15. EMBO J 12:75-85 (1993).
112. Booher RN, Holman PS, Fattaey A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 272: 22300-22306 (1997).
113. cdc2 in a wee1+ dependent manner. EMBO J 10:1255-1263 (1991).
114. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M. Beach D. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 64:1111-1122 (1991).
115. cdc2 regulation. Mol Cell Biol 13:1675-1685 (1993).
116. cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351:242-245 (1991).
117. cdc2. Cell 67:197-211 (1991).
118. Kumagai A, Dunphy WG. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell 64:903-914 (1991).
119. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2/cyclin-B and its involvement in the self-amplification of MPF at mitosis. EMBO J 12:53-63 (1993).
120. Kumagai A, Dunphy WG. Regulation of the cdc25 protein during the cell cycle in Xenopus extracts. Cell 70:139-151 (1992).
121. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci USA 93:4827-4832 (1996).
122. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 274:1664-1672 (1996).
123. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 266.1821-1828 (1994).
124. Little JB. Delayed initiation of DNA synthesis in irradiated human diploid cells. Nature 218:1064-1065 (1968).
125. Kastan MB, Onyekere O, Sidransky D, Volgelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311 (1991).
126. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumour antigen in nontransfotmed mouse cells. Mol Cell Biol 4:1689-1694 (1984).
127. Campbell C, Quinn AG, Angus B, Farr PM, Rees JL. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 53:2697-2699 (1993).
128. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823 (1994).
129. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540-2551 (1994).
130. 1/S cell cycle checkpoint defect in Ataxia-telangiectasia. Oncogene 11:609-618 (1995).
131. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711 (1991).
132. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871 (1992).
133. Kastan MB, Zhan Q, el DW, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJJ. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-telangiectasia. Cell 71:587-597 (1992).
134. 1 arrest and apoptosis. Cancer Res 54:1169-1174 (1994).
135. Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8:1183-1193 (1993).
136. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704 (1993).
137. 1 cyclin-dependent kinases. Cell 75:805-816 (1993).
138. 1 arrest. Cell 76:1013-1023 (1994).
139. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang PM, Dobrowolski S, Bai C, Connellcrowley L, Swindell E, Fox MP, Wei N. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400 (1995).
140. 2/M-phase transition. Mol Cell Biol 18:546-557 (1998).
141. 1 checkpoint control. Cell 82:675-684 (1995).
142. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397-3406 (1994).
143. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391-3395 (1994).
144. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944 (1995).
145. WAF1/CIP1 expression in pericentral hepatocytes following carbon tetrachloride intoxication. Cell Growth Differ 8:951-961 (1997).
146. Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027 (1995).
147. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750-1758 (1994).
148. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578 (1994).
149. Cistulli CA, Kaufmann WK. p53-dependent signaling sustains DNA replication and enhances clonogenic survival in 254 nm ultraviolet-irradiated human fibroblasts. Cancer Res 58:1993-2002 (1998).
150. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74 (1994).
151. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662 (1995).
152. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin-D/CDK4. Nature 366:704-707 (1993).
153. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503-506 (1995).
154. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37 (1996).
155. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene 11:1211-1216 (1995).
156. Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, Tsunoda H, Kubo T, Miwa M, Uchida K. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 69:466-470 (1996).
157. Lo KW, Cheung ST, Leung SF, van-Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC, Huang DP. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725 (1996).
158. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20 (1997).
159. ARF. Cell 91:649-659 (1997).
160. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000 (1995).
161. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723 (1998).
162. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 11:3995-4005 (1992).
163. Sebastian B, Kakizuka A, Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 90:3521-3524 (1993).
164. 1 arrest induced by ultraviolet irradiation. Nature 376:358-362 (1995).
165. 0-like arrest. Mol Cell Biol 16:3934-3944 (1996).
166. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, Okayama H. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13:1549-1556 (1994).
167. Makino F, Okada S. Effects of ionizing radiation on DNA replication in cultured mammalian cells. Radiat Res 62:37-51 (1975).
168. Painter RB, Young BR. X-ray-induced inhibition of DNA synthesis in Chinese hamster ovary, human HeLa, and mouse L cells. Radiat Res 64:648-656 (1975).
169. Painter RB, Young BR. Formation of nascent DNA molecules during inhibition of replicon initiation in mammalian cells. Biochim Biophys Acta 418:146-153 (1976).
170. Painter RB, Young BR. Radiosensitivity in Ataxia-telangiectasia: a new explanation. Proc Natl Acad Sci USA 77:7315-7317 (1980).
171. Larner JM, Lee H, Hamlin JL. Radiation effects on DNA synthesis in a defined chromosomal replicon. Mol Cell Biol 14:1901-1908 (1994).
172. Cleaver JE, Rose R, Mitchell DL. Replication of chromosomal and episomal DNA in X-ray-damaged human cells: a cis-or trans-acting mechanism? Radiat Res 124:294-299 (1990).
173. Beamish H, Williams R, Chen P, Lavin MF. Defect in multiple cell cycle checkpoints in Ataxia-telangiectasia postirradiation. J Biol Chem 271:20486-20493 (1996).
174. 2 arrest in Chinese hamster ovary cells. Cancer Res 50:3761-3766 (1990).
175. cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res 50:3767-3771 (1990).
176. 2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res 55:1763-1773 (1995).
177. 2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene 11:2151-2156 (1995).
178. Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 134:963-970 (1996).
179. 2 arrest induced by nitrogen mustard. Proc Natl Acad Sci USA 91:9480-9484 (1994).
180. Sanchez Y, Wong C, Thoma RS, Richman R, Wu RQ, Piwnica-Worms H, Elledge SJ. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497-1501 (1997).
181. 2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501-1505 (1997).
182. Weinert T. Cell cycle - a DNA damage checkpoint meets the cell cycle engine. Science 277: 1450-1451 (1997).
183. Zampetti-Bosseler F, Scott D. Cell death, chromosome damage and mitotic delay in normal human, Ataxia telangiectasia and retinoblastoma fibroblasts after X-irradiation. Int J Radiat Biol 39:547-558. (1981).
184. Scott D, Zampetti-Bosseler F. Cell cycle dependence of mitotic delay in X-irradiated normal and Ataxia telangiectasia fibroblasts. Int J Radiat Biol 42:679-683 (1982).
185. Nagasawa H, Latt SA, Lalande ME, Little JB. Effects of X-irradiation on cell cycle progression, induction of chromosomal aberrations and cell killing in Ataxia telangiectasia (AT) fibroblasts. Mutat Res 148:71-82 (1985).
186. Beamish H, Lavin MF. Radiosensitivity in Ataxia-telangiectasia: anomalies in radiation-induced cell cycle delay. Int J Radiat Biol 65:175-184 (1994).
187. 2 blocks, cyclin B expression and cdc2 expression in human squamous carcinoma cell lines with different radiosensitivities. Radiother Oncol 33:217-227 (1994).
188. 2 checkpoint. EMBO J 17:2728-2735 (1998).
189. Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141:875-885 (1998).
190. 2 block induced by ionizing radiation. Cancer Res 51:5113-5117 (1991).
191. Muschel RJ, Zhang HB, McKenna WG. Differential effect of ionizing radiation on the expression of cyclin A and cyclin B in HeLa cells. Cancer Res 53:1128-1135 (1993).
192. Maity A, Mckenna WG, Muschel RJ. Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J 14:603-609 (1995).
193. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res 52:1817-1822 (1992).
194. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 268:8298-8308 (1993).
195. Barth H, Hoffmann I, Kinzel V. Radiation with 1 Gy prevents the activation of the mitotic inducers mitosis-promoting factor (MPF) and cdc25-C in HeLa cells. Cancer Res 56:2268-2272 (1996).
196. Poon RYC, Jiang W, Toyoshima H, Hunter T. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271:13283-13291 (1996).
197. Poon RYC, Chau MS, Yamashita K, Hunter T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57:5168-5178 (1997).
198. Rice RH, Steinmann KE, deGraffenried LA, Qin Q, Taylor N, Schlegel R. Elevation of cell cycle control proteins during spontaneous immortalization of human keratinocytes. Mol Biol Cell 4:185-194 (1993).
199. Steinmann KE, Pei XF, Stoppler H, Schlegel R, Schlegel R. Elevated expression and activity of mitotic regulatory proteins in human papillomavirus immortalized keratinocytes. Oncogene 9:387-394 (1994).
200. 2 checkpoint function precedes human cell immortalization. Cancer Res 55:7-11 (1995).
201. 2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ 8:1105-1114 (1997).
202. Chang THT, Ray FA. Thompson DA, Schlegel R. Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells. Oncogene 14:2383-2393 (1997).
203. 2 checkpoint response to ionizing radiation. Cancer Res 55:2500-2502 (1995).
204. Murray AW. The genetics of cell cycle checkpoints. Curr Opin Genet Dev 5:5-11 (1995).
205. Rudner AD, Murray AW. The spindle assembly checkpoint. Curr Opin Cell Biol 8:773-780 (1996).
206. Hardwick KG. The spindle checkpoint. Trends Genet 14:1-4 (1998).
207. King RW, Peters JM, Tugendreich S, Rolfe M, Nieter P, Kirschner MW. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81:279-288 (1995).
208. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 274:1652-1659 (1996).
209. Cohen-Fix D, Koshland D. The metaphase-to-anaphase transition: avoiding a mid-life crisis. Curr Opin Cell Biol 9:800-806 (1997).
210. 1 cyclins in the next cycle. Cell 77:1037-1050 (1994).
211. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV, Hershko A. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 6:185-197 (1995).
212. Cohen-Fix O, Peters JM, Kirschner MW, Koshland D. Anaphase initiation in Saccharomyces cerevisiae is controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p. Genes Dev 10:3081-3093 (1996).
213. Cohen-Fix O, Koshland D. The anaphase inhibitor of Saccharomyces cerevisiae Pds1p is a target of the DNA damage checkpoint pathway. Proc Natl Acad Sci USA 94:14361-14366 (1997).
214. Juang YL, Huang J, Peters JM, McLaughlin ME, Tai CY, Pellman D. APC-mediated proteolysis of Ase 1 and the morphogenesis of the mitotic spindle. Science 275:1311-1314 (1997).
215. Zieve GW, Turnbull D, Mullins JM, McIntosh JR. Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 126:397-405 (1980).
216. Kung AL, Sherwood SW, Schimke RT. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA 87:9553-9557 (1990).
217. Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol 127:1301-10 (1994).
218. Li XT, Nicklas RB. Mitotic forces control a cell-cycle checkpoint. Nature 373:630-632 (1995).
219. Fang GW, Yu HT, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 12:1871-1883 (1998).
220. Hwang LH, Lau LF, Smith DL, Mistrot CA, Hardwick KG, Hwang ES, Amon A, Murray AW. Budding yeast Cdc20: a target of the spindle checkpoint. Science 279:1041-1044 (1998).
221. Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of PLK1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 129:1617-1628 (1995).
222. Hamanaka R, Smith MR, O'Connor PM, Maloid S, Mihalic K, Spivak JL, Longo DL, Ferris DK. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 270:21086-21091 (1995).
223. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135:1701-1713 (1996).
224. Descombes P, Nigg EA. The polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. EMBO J 17:1328-1335 (1998).
225. Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, Hieter P, Todokoro K. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol Cell 1:371-380 (1998).
226. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 274:246-248 (1996).
227. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 392:300-303 (1998).
228. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356 (1995).
229. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 57:1013-1019 (1997).
230. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055-1064 (1998).
231. 1 arrest. Cancer Res 58:396-401 (1998).
232. Walters RA, Gurley LR, Tobey RA. Effects of caffeine on radiation-induced phenomena associated with cell-cycle traverse of mammalian cells. Biophys J 14:99-118 (1974).
233. Snyder MH, Kimler BF, Leeper DB. The effect of caffeine on radiation-induced division delay. Int J Radiat Biol Relat Stud Phys Chem Med 32:281-284 (1977).
234. Tolmach LJ, Jones RW, Busse PM. The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiat Res 71:653-65 (1977).
235. 2 delay. Radiat Res 74:112-128 (1978).
236. Schlegel R, Pardee AB. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science 232:1264-1266 (1986).
237. 2 arrest by caffeine. Radiat Res 129:224-227 (1992).
238. 2-phase cell cycle blocks are equally released by caffeine. Radiat Res 135:372-379 (1993).
239. Fingert HJ, Chang JD, Pardee AB. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res 46:2463-2467 (1986).
240. Musk SR, Steel GG. Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Int J Radiat Biol 57:1105-1112 (1990).
241. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 11:1555-1560 (1991).
242. 1 checkpoint-competent cells. Cancer Res 55:1639-1642 (1995).
243. 2 delay. Cancer Res 55:1643-1648 (1995).
244. Lau CC, Pardee AB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79:2942-2946 (1982).
245. Boder E, Sedgwick RP. Ataxia-telangiectasia. (Clinical and immunological aspects). Psychiatr Neural Med Psychol Beih 14:8-16 (1970).
246. Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser 19:1-63 (1985).
247. Sedgwick RP, Boder E. Ataxia-telangiectasia. In: Handbook of Clinical Neurology. Vol 6 (Vinkins PJ, Bruyn GW, Klawans HL, eds). New York:Elsevier Science Publishers B.V., 1991:347-423.
248. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by Ataxia-telangiectasia. N Engl J Med 325:1831-6 (1991).
249. Meyn MS. High spontaneous intrachromosomal recombination rates in Ataxia-telangiectasia. Science 260:1327-1330 (1993).
250. Easton DF. Cancer risks in A-T heterozygotes. Int. J Radiat Biol 66:S177-S182 (1994).
251. Shiloh Y, Tabor E, Becker Y. Colony-forming ability of Ataxia-telangiectasia skin fibroblasts is an indicator of their early senescence and increased demand for growth factors. Exp Cell Res 140:191-199 (1982).
252. 2 delay and spontaneous chromosome aberrations in Ataxia-telangiectasia homozygotes and heterozygotes. Int J Radiat Biol 66:S157-S163 (1994).
253. Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, Ersoy F, Foroud T, Jaspers NG, Lange K, et al. Localization of an Ataxia-telangiectasia gene to chromosome 11q22-23. Nature 336:577-580 (1988).
254. McKinnon PJ. Ataxia-telangiectasia: an inherited disorder of ionizing-radiation sensitivity in man. Hum Genet 75:197-208 (1987).
255. Savitsky K, Barshira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al. A single Ataxia telangiectasia gene with a product similar to Pl-3 kinase. Science 268:1749-1753 (1995).
256. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4:2025-2032 (1995).
257. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679 (1998).
258. Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677 (1998).
259. Rotman G, Shiloh Y. Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress? Bioessays 19:911-917 (1997).
260. Khanna KK, Lavin MF. Ionizing radiation and UV induction of p53 protein by different pathways in Ataxia-telangiectasia cells. Oncogene 8:3307-3312 (1993).
261. 1 cell cycle checkpoint pathway and Ataxia-telangiectasia. Cancer Res 54:5054-5058 (1994).
262. n and DNA synthesis in Ataxia telangiectasia cells following γ-ray irradiation. Nature 287:745-747 (1980).
263. Houldsworth J, Lavin MF. Effect of ionizing radiation on DNA synthesis in Ataxia telangiectasia cells. Nucleic Acids Res 8:3709-3720 (1980).
264. Xie GF, Habbersett RC, Jia YW, Peterson SR, Lehnert BE, Bradbury EM, Danna JA. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. Oncogene 16:721-736 (1998).
265. Lehman AR, Stevens S. The production and repair of double strand breaks in cells from normal humans and from patients with Ataxia telangiectasia. Biochim Biophys Acta 474:49-60 (1977).
266. Fornace AJ Jr, Little JB. Normal repair of DNA single-strand breaks in patients with Ataxia telangiectasia. Biochim Biophys Acta 607: 432-437 (1980).
267. Ward AJ, Olive PL, Burr AH, Rosin MP. Response of fibroblast cultures from Ataxia-telangiectasia patients to reactive oxygen species generated during inflammatory reactions. Environ Mol Mutagen 24:103-111 (1994).
268. Taylor AM. Unrepaired DNA strand breaks in irradiated Ataxia telangiectasia lymphocytes suggested from cytogenetic observations. Mutat Res 50:407-418 (1978).
269. Cornforth MN, Bedford JS. On the nature of a defect in cells from individuals with Ataxia-telangiectasia. Science 227:1589-1591 (1985).
270. 2 cell-cycle period of skin fibroblasts from individuals with familial cancer. Proc Natl Acad Sci USA 82:5400-5403 (1985).
271. Pandita TK, Hittelman WN. The contribution of DNA and chromosome repair deficiencies to the radiosensitivity of Ataxia-telangiectasia. Radiat Res 131:214-223 (1992).
272. Hittelman WN, Pandita TK. Possible role of chromatin alteration in the radiosensitivity of Ataxia-telangiectasia. Int J Radiat Biol 66:S109-S113 (1994).
273. 2 chromosomal radiosensitivity in fibroblasts of Ataxia-telangiectasia heterozygotes and a Li-Fraumeni Syndrome patient with radioresistant cells. Int J Radiat Biol 72:435-438 (1997).
274. Shiloh Y, Tabor E, Becker Y. Abnormal response of aAtaxia-telangiectasia cells to agents that break the deoxyribose moiety of DNA via a targeted free radical mechanism. Carcinogenesis 4:1317-1322 (1983).
275. Dar ME, Winters TA, Jorgensen TJ. Identification of defective illegitimate recombinational repair of oxidatively-induced DNA double-strand breaks in Ataxia-telangiectasia cells. Mutat Res 384:169-179 (1997).
276. Vuillaume M. Reduced oxygen species, mutation, induction and cancer initiation. Mutat Res 186:43-72 (1987).
277. Meredith MJ, Dodson ML. Imparied glutathione biosynthesis in cultured human Ataxia-telangiectasia cells. Cancer Res 47:4576-4581 (1987).
278. 2 disproportionation in extracts from normal and Xeroderma pigmentosum skins, and from normal, Xeroderma pigmentosum, Ataxia telangiectasia and simian virus 40 transformed cell lines. Carcinogenesis 10:1375-1381 (1989).
279. Green MHL, Marcovitch AJ, Harcourt SA, Lowe JE, Green IC, Arlett CF. Hypersensitivity of ataxia-telangiectasia fibroblasts to a nitric oxide donor. Free Radic Biol Med 22:343-347 (1997).
280. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823 (1971).
281. Knudson AG Jr. Hereditary cancers disclose a class of cancer genes. Cancer 63:1888-1891 (1989).
282. Weichselbaum RR, Beckett M, Diamond A. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 85:2106-2109 (1988).
283. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394-1399 (1987).
284. Weintraub SJ. Inactivation of tumor suppressor proteins in lung cancer. Am J Respir Cell Mol Biol 15:150-155 (1996).
285. Harbour JW, Lai SL, Whang Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357 (1988).
286. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218-221 (1988).
287. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4:829-834 (1998).
288. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58:1090-1094 (1998).
289. Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, Benedict WF, Takahashi R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51:5736-5743 (1991).
290. Sanders BM, Jay M, Draper GJ, Roberts EM. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 60:358-365 (1989).
291. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294 (1992).
292. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 359:295-300 (1992).
293. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027 (1994).
294. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666-677 (1994).
295. Almasan A, Linke SP, Paulson TG, Huang LC, Wahl GM. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev 14:59-73 (1995).
296. Reznitoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, Thompson KJ, DeVries S, Bindley C, Newton MA, et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-immortalized human uroepithelial cells. Genes Dev 8:2227-2240 (1994).
297. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Annu Intern Med 71:747-752 (1969).
298. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362 (1988).
299. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Jr., Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51:6094-6097 (1991).
300. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 76:1-14 (1997).
301. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238 (1990).
302. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome Nature 348:747-749 (1990).
303. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245-3252 (1997).
304. Bischoff F, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 50:7979-7984 (1990).
305. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495 (1992).
306. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935 (1992).
307. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948 (1992).
308. 2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat Res 136:235-240 (1993).
309. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence JJ, May P, Oren M. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 13:1415-1423 (1993).
310. Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, Englezou A, Warneford SG, Dalla-Pozza L, Reddel RR. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 15:4745-4753 (1995).
311. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond) 356:215-221 (1992).
312. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5:225-229 (1993).
313. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8:66-69 (1994).
314. Oren M. p53: the ultimate tumor suppressor gene? FASEB J 6:3169-3176 (1992).
315. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitts lymphoma cell lines. Cancer Res 53:4776-4780 (1993).
316. Srivastava S, Wang S, Tong YA, Hao ZM, Chang EH. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res 53:4452-4455 (1993).
317. Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 13:5186-5194 (1993).
318. Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev 10:826-835 (1996).
319. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88:323-331 (1997).
320. Varghese AJ, Wang SY. Thymine-thymine adduct as a photoproduct of thymine. Science 160:186-187 (1968).
321. Varghese AJ, Patrick MH. Cytosine derived heteroadduct formation in ultraviolet-irradiated DNA. Nature 223:299-300 (1969).
322. Varghese AJ. Photochemistry of nucleic acids and their constituents. Photophysiology 7:207-274 (1972).
323. Lober G, Kittler L. Selected topics in photochemistry of nucleic acids. Recent results and perspectives. Photochem Photobiol 25:215-233 (1977).
324. Tyrrell RM. UV activation of mammalian stress proteins. EXS 77:255-271 (1996).
325. Tyrrell RM. Activation of mammalian gene expression by the UV component of sunlight -from models to reality. Bioessays 18:139-148 (1996).
326. Black HS, de Gruijl FR, Forbes PD, Cleaver JE, Ananthaswamy HN, de Fabo EC, Ullrich SE, Tyrrell RM. Photocarcinogenesis: an overview. J Photochem Photobiol B 40:29-47 (1997).
327. Kvam E, Tyrrell RM. Induction of oxidative DNA base damage in human skin cells by UV and near visible radiation. Carcinogenesis 18:2379-2384 (1997).
328. Setlow RB. Cyclobutane-type pyrimidine dimers in polynucleotides. Science 153:379-386 (1966).
329. Setlow RB, Carrier WL. Pyrimidine dimers in ultraviolet-irradiated DNA's. J Mol Biol 17:237-254 (1966).
330. Setlow RB. The photochemistry, photobiology, and repair of polynucleotides. Prog Nucleic Acid Res Mol Biol. 8:257-295 (1968).
331. Liu M, Pelling JC. UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression. Oncogene 10:1955-1960 (1995).
332. Kaufmann WK. Pathways of human cell post-replication repair. Carcinogenesis 10:1-11 (1989).
333. Cordeiro-Stone M, Zaritskaya LS, Price LK, Kaufmann WK. Replication fork bypass of a pyrimidine dimer blocking leading strand DNA synthesis. J Biol Chem 272:13945-13954 (1997).
334. Rosette C, Karin M. Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274:1194-1197 (1996).
335. Roddey PK, Garmyn M, Park HY, Bhawan J, Gilchrest BA. Ultraviolet irradiation induces c-fos but not c-Ha-ras proto-oncogene expression in human epidermis. J Invest Dermatol 102:296-299 (1994).
336. Matsui MS, DeLeo VA. Induction of protein kinase C activity by ultraviolet radiation. Carcinogenesis 11:229-234 (1990).
337. Yarosh DB, Kripke ML. DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Mutat Res 350:255-260 (1996).
338. Scotto J, Fears TR. The association of solar ultraviolet and skin melanoma incidence among Caucasians in the United States. Cancer Invest 5:275-283 (1987).
339. Dalziel KL. Aspects of cutaneous ageing. Clin Exp Dermatol 16:315-323 (1991).
340. Kricker A, Armstrong BK, English DR. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control 5:367-392 (1994).
341. English DR, Armstrong BK, Kricker A, Fleming C. Sunlight and cancer. Cancer Causes Control 8:271-283 (1997).
342. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol 133:1263-1270 (1997).
343. Yarosh D, Alas LG, Yee V, Oberyszyn A, Kibitel JT, Mitchell D, Rosenstein R, Spinowitz A, Citron M. Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res 52:4227-4231 (1992).
344. Cleaver JE. Defective repair replication of DNA in Xeroderma pigmentosum. Nature 218:652-656 (1968).
345. Cleaver JE. Xeroderma pigmentosum: a human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci USA 63:428-435 (1969).
346. Setlow RB, Regan JD, German J, Carrier WL. Evidence that Xeroderma pigmentosum cells do not perform the first step in the repair of ultraviolet damage to their DNA. Proc Natl Acad Sci USA 64:1035-1041 (1969).
347. Pawsey SA, Magnus IA, Ramsay CA, Benson PF, Giannelli F. Clinical, genetic and DNA repair studies on a consecutive series of patients with Xeroderma pigmentosum. Q J Med 48:179-210 (1979).
348. Kaufmann WK, Cleaver JE. Mechanisms of inhibition of DNA replication by ultraviolet light in normal human and Xeroderma pigmentosum fibroblasts. J Mol Biol 149:171-187 (1981).
349. Timme TL, Moses RE. Diseases with DNA damage-processing defects. Am J Med Sci 295:40-48 (1988).
350. Weeda G, van Ham RC, Vermeulen W, Bootsma D, van der Eb AJ, Hoeijmakers JH. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders Xeroderma pigmentosum and Cockayne's syndrome. Cell 62:777-791 (1990).
351. Tanaka K, Miura N, Satokata I, Miyamoto I, Yoshida MC, Satoh Y, Kondo S, Yasui A, Okayama H, Okada Y. Analysis of a human DNA excision repair gene involved in group A Xeroderma pigmentosum and containing a zinc-finger domain. Nature 348:73-76 (1990).
352. Boyer JC, Kaufmann WK, Brylawski BP, Cordeiro-Stone M. Defective postreplication repair in Xeroderma pigmentosum variant fibroblasts. Cancer Res 50:2593-2598 (1990).
353. Bootsma D, Hoeijmakers JH. The genetic basis of Xeroderma pigmentosum. Ann Genet 34:143-150 (1991).
354. Legerski R, Peterson C. Expression cloning of a human DNA repair gene involved in Xeroderma pigmentosum group C. Nature 359:70-73 (1992).
355. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, Hoeijmakers JH, Chambon P, Egly JM. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science 260:58-63 (1993).
356. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yen H, Hoeijmakers JH, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10:1219-1232 (1996).
357. Cleaver JE, States JC. The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein. Biochem J 328:1-12 (1997).
358. Sands AT, Abuin A, Sanchez A, Conti CJ, Bradley A. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377:162-165 (1995).
359. Nakane H, Takeuchi S, Yuba S, Saijo M, Nakatsu Y, Murai H, Nakatsuru Y, Ishikawa T, Hirota S, Kitamura Y, et al. High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the Xeroderma pigmentosum group A gene. Nature 377:165-168 (1995).
360. de Vries A, van Oostrom CTM, Hofhuis FMA, Dortant PM, Berg RJW, de Gruijl FR, Wester FW, van Kreijl CF, Capel PJA, van Steeg H, et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377:169-173 (1995).
361. Muller HJ. Artificial transmutation of the gene. Science 66:84-87 (1927).
362. Cerutti PA. DNA base damage induced by ionizing radiation. In: Photochemistry and Photobiology of Nucleic Acids (Wang SY, ed). New York: Academic Press, 1976;375-401.
363. Shellabarger CJ. Radiation carcinogenesis: laboratory studies. Cancer 37:1090-1096 (1976).
364. Tokunaga M, Norman JE Jr, Asano M, Tokuoka S, Ezaki H, Nishimori I, Tsuji Y. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. J Natl Cancer Inst 62:1347-1359 (1979).
365. Hutchinson F. Chemical changes induced in DNA by ionizing radiation. Prog Nucleic Acid Res Mol Biol 32:115-154 (1985).
366. Goodhead DT. The initial physical damage produced by ionizing radiations. Int. J Radiat Biol 56:623-634 (1989).
367. Nikjoo H, O'Neill P, Terrissol M, Goodhead DT. Modelling of radiation-induced DNA damage: the early physical and chemical event. Int J Radiat Biol 66:453-457 (1994).
368. Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 65:7-17 (1994).
369. Morgan WF, Day JP, Kaplan MI, McGhee EM, Limoli CL. Genomic instability induced by ionizing radiation. Radiat Res 146:247-258 (1996).
370. Shimizu Y, Kato H, Schull WJ. Risk of cancer among atomic bomb survivors. J Radiat Res 2:54-63 (1991).
371. Otake M, Schull WJ, Lee S. Threshold for radiation-related severe mental retardation in prenatally exposed A-bomb survivors: a re-analysis. Int J Radiat Biol 70:755-763 (1996).
372. Blot WJ. Growth and development following prenatal and childhood exposure to atomic radiation. J Radiat Res Tokyo 16:82-88 (1975).
373. Skov KA. The contribution of hydroxyl radical to radiosensitization: a study of DNA damage. Radiat Res 99:502-510 (1984).
374. Teoule R. Radiation-induced DNA damage and its repair. Int J Radiat Biol 51:573-589 (1987).
375. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol 35:95-125 (1988).
376. Adams GED. Radiation carcinogenesis. In: Introduction to the Cellular and Molecular Biology of Cancer (Franks LM, Teich N, eds), New York:Oxford University Press, 1986; 154-175.
377. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65:27-33 (1994).
378. Jostes RF. Genetic, cytogenetic, and carcinogenic effects of radon: a review. Mutat Res 340:125-139 (1996).
379. Little JB. What are the risks of low-level exposure to alpha radiation from radon? Proc Natl Acad Sci USA 94:5996-5997 (1997).
380. van Hoff J, Averkin YI, Hilchenko EI, Prudyvus IS. Epidemiology of childhood cancer in Belarus: review of data 1978-1934, and discussion of the new Belarusian Childhood Cancer Registry. Stem Cells 2:231-241 (1997).
381. Sohrabi M. The state-of-the-art on worldwide studies in some environments with elevated naturally occurring radioactive materials (NORM). Appl Radiat Isot 49:169-188 (1998).
382. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 91:4130-4134 (1994).
383. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor PM, Anderson CW, Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270:29386-29391 (1995).
384. 1 arrest but not cell replication. Biochem J 332:43-50 (1998).
385. Harman DJ. Aging: a theory based on free radical and radiation chemistry. Gerontology 11:298-300 (1956).
386. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 4:2587-2597 (1990).
387. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 69:261-274 (1993).
388. Ames BN, Shigenaga MK. Oxidants are a major contributor to aging. Ann NY Acad Sci 663:85-96 (1992).
389. Martin GM, Austad SN, Johnson TE. Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat Genet 13:25-34 (1996).
390. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 273:59-63 (1996).
391. Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinog 3:188-197 (1990).
392. Forman HJ, Boveris A. Superoxide radical and hydrogen peroxide in mitochondria. In: Free Radicals in Biology (Pryor E, ed). New York: Academic Press, 1982;65-90.
393. Dizdaroglu M, Rao G, Halliwell B, Gajewski E. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch Biochem Biophys 285:317-324 (1991).
394. Imlay JA, Chin SM, Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro. Science 240:640-642 (1988).
395. Michalik V, Maurizot MS, Charlier M. Calculation of hydroxyl radical attack on different forms of DNA. J Biomol Struct Dyn 13:565-575 (1995).
396. Keyer K, Imlay JA. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci USA 93:13635-13640 (1996).
397. Malins DC, Holmes EH, Polissar NL, Gunselman SJ. The etiology of breast cancer. Characteristic alteration in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 71:3035-3043 (1993).
398. Senturker S, Karahalil B, Inal M, Yilmaz H, Muslumanoglu H, Gedikoglu G, Dizdaroglu M. Oxidative DNA base damage and antioxidant enzyme levels in childhood acute lymphoblastic leukemia. FEBS Lett 416:286-290 (1997).
399. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 4:875-882 (1997).
400. Erhardt JG, Lim SS, Bode JC, Bode C. A diet rich in fat and poor in dietary fiber increases the in vitro formation of reactive oxygen species in human feces. J Nutr 127:706-709 (1997).
401. Thome J, Zhang J, Davids E, Foley P, Weijers HG, Wiesbeck GA, Boning J, Riederer P, Gerlach M. Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products. Alcohol Clin Exp Res 21:82-85 (1997).
402. Valavanidis A, Balomenou H, Macropoulou I, Zarodimos I. A study of the synergistic interaction of asbestos fibers with cigarette tar extracts for the generation of hydroxyl radicals in aqueous buffer solution. Free Radic Biol Med 20:853-858 (1996).
403. Nagata C, Kodama M, Ioki Y, Kimura T. Free radicals produced from chemical carcinogens and their signifance in carcinogenesis. In: Free Radicals and Cancer (Floyd RA, ed). New York:Marcel Dekker, 1982;1-62.
404. Moran LA, Scrimgeour KG, Horton HR, Ochs RS, Rawn JD. Biochemistry. Englewood Cliffs, NJ:Neil Patterson Publishers, 1995;1824-1825.
405. Skulachev VP. Aging is a specific biological function rather than the result of a disorder in complex living systems: biochemical evidence in support of Weismann's hypothesis. Biochemistry (Mosc) 62:1191-1195 (1997).
406. Mello-Filho AC, Meneghini R. In vivo formation of single-strand breaks in DNA by hydrogen peroxide is mediated by the Haber-Weiss reaction. Biochim Biophys Acta 781:56-63 (1984).
407. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59:527-605 (1979).
408. Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Genet 19:171-174 (1998).
409. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 78:915-918 (1994).
410. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620-1624 (1990).
411. Yoshie Y, Ohshima H. Synergistic induction of DNA strand breakage by cigarette tar and nitric oxide. Carcinogenesis 18:1359-1363 (1997).
412. O'Connor PM, Ferris DK, White GA, Pines J, Hunter T, Longo DL, Kohn KW. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 3:43-52 (1992).
413. 2/M when it is transactivation defective. EMBO J 14:4994-5005 (1995).
414. Fan SJ, Smith ML, Rivet DJ, Duba D, Zhan QM, Kohn KW, Fornace AJ, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1549-1654 (1995).
415. Ceraline J, Deplanque G, Duclos B, Limacher JM, Vincent F, Goldblum S, Bergerat JP. Relationships between p53 induction, cell cycle arrest and survival of normal human fibroblasts following DNA damage. Bull Cancer 84:1007-1016 (1997).
416. Fan SJ, Chang JK, Smith ML, Duba D, Fornace AJ, O'Connor PM. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127-2136 (1997).
417. 1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 13:625-632 (1996).
418. 1/S and intra-S DNA damage checkpoints in budding yeast. Nucleic Acids Res 24:3533-3537 (1996).
419. 2 cell cycle checkpoint. Cancer Res 55:3721-3725 (1995).
420. Albert RE, Burns FJ. Carcinogenic atmospheric pollutants and the nature of low-level risks. In: Origins of Human Cancer (Hiatt HH, Watson JD, Winston JA, eds). Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press, 1977;289-292.
421. Doll R. Pott and the path to prevention. Arch Geschwulstforsch 45:521-531 (1975).
422. Phillips DH. Fifty years of benzo(a)pyrene. Nature 303:468-472 (1983).
423. Gelboin HV. Carcinogens, enzyme induction, and gene action. Adv Cancer Res 10:1-81 (1967).
424. Wood AW, Levin W, Lu AY, Yagi H, Hernandez O, Jerina DM, Conney AH. Metabolism of benzo(a)pyrene and benzo (a)pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J Biol Chem 251: 4882-4890 (1976).
425. Marquardt H, Grover PL, Sims P. In vitro malignant transformation of mouse fibroblasts by non-K-region dihydrodiols derived from 7-methylbenz(a)anthracene, 7,12-dimethylbenz(a)-anthracene, and benzo(a)pyrene. Cancer Res 36:2059-2064 (1976).
426. Buening MK, Wislocki PG, Levin W, Yagi H, Thakker DR, Akagi H, Koreeda M, Jerina DM, Conney AH. Tumorigenicity of the optical enantiomers of the diastereomeric benzo[a]pyrene 7,8-diol-9,10-epoxides in newborn mice: exceptional activity of (+)-7β8α-dihydroxy-9α, 10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Proc Natl Acad Sci USA 75:5358-5361 (1978).
427. Kapitulnik J, Wislocki PG, Levin W, Yagi H, Jerina DM, Conney AH. Tumorigenicity studies with diol-epoxides of benzo(a)pyrene which indicate that (+/-)-trans-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10- tetrahydrobenzo(a)pyrene is an ultimate carcinogen in newborn mice. Cancer Res 38:354-358 (1978).
428. Weinstein IB, Jeffrey AM, Jennette KW, Blobstein SH, Harvey RG, Harris C, Autrup H, Kasai H, Nakanishi K. Benzo(a)pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo. Science 193:592-595 (1976).
429. Chen L, Devanesan PD, Higginbotham S, Ariese F, Jankowiak R, Small GJ, Rogan EG, Cavalieri EL. Expanded analysis of benzo[a]pyrene-DNA adducts formed in vitro and in mouse skin: their significance in tumor initiation. Chem Res Toxicol 9:897-903 (1996).
430. Cavalieri EL, Rogan EG. Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Xenobiotica 25:677-688 (1995).
431. Hsu IC, Bowden GT, Harris CC. A comparison of cytotoxicity, ouabain-resistant mutation, sister-chromatid exchanges, and nascent DNA synthesis in Chinese hamster cells treated with dihydrodiol epoxide derivatives of benzo[a]pyrene. Mutat Res 63:351-359 (1979).
432. Kaufmann WK, Boyer JC, Smith BA, Cordeiro Stone M. DNA repair and replication in human fibroblasts treated with (+/-)-r-7, t-8-dihydroxy-t-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Biochim Biophys Acta 824:146-151 (1985).
433. Cordeiro-Stone M, Boyer JC, Smith BA, Kaufmann WK. Effect of benzo[a]pyrene-diol-epoxide-l on growth of nascent DNA in synchronized human fibroblasts. Carcinogenesis 7:1775-1781 (1986).
434. Yamanishi DT, Bowden GT, Cress AE. An analysis of DNA replication in synchronized CHO cells treated with benzo[a]pyrene diol epoxide. Biochim Biophys Acta 910:34-42 (1987).
435. Paules RS, Cordeiro-Stone M, Mass MJ, Poirier MC, Yuspa SH, Kaufman DG. Benzo[alpha]pyr ene diol epoxide l binds to DNA at replication forks. Proc Natl Acad Sci USA 85:2176-2180 (1988).
436. Black KA, McFarland RD, Grisham JW, Smith GJ. S-phase block and cell death in human lymphoblasts exposed to benzo[a]pyrene diol epoxide or N-acetoxy-2-acetylaminofluorene. Toxicol Appl Pharmacol 97:463-472 (1989).
437. Kaufmann WK. Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer Metastasis Rev 14:31-41 (1995).
438. Yang LL, Maher VM, McCormick JJ. Relationship between excision repair and the cytotoxic and mutagenic effect of the 'anti' 7,8-diol-9,10-epoxide of benzo[a]pyrene in human cells. Mutat Res 94:435-447 (1982).
439. Yang JL, Maher VM, McCormick JJ. Kinds of mutations formed when a shuttle vector containing adducts of (+/-)-7 β, 8 α-dihydroxy-9 α, 10 α-epoxy-7,8,9, 10-tetrahydrobenzo[a]pyrene replicates in human cells. Proc Natl Acad Sci USA 84:3787-3791 (1987).
440. Yang JL, Chen RH, Maher VM, McCormick JJ. Kinds and location of mutations induced by (+/-)-7 β,8 α-dihydroxy-9 α,10 α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase gene in diploid human fibroblasts. Carcirogenesis 12:71-75 (1991).
441. Wu X, Zhao Y, Honn SE, Tomlinson GE, Minna JD, Hong WK, Spitz MR. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 58:1605-1608 (1998).
442. Groopman JD, Cain LG. Interactions of fungal and plant toxins with DNA: aflatoxins, sterigmacystin, safrole, cycasin, and pyrrolizidine alkaloids. In: Chemical Carcinogenesis and Mutagenesis I (Cooper CS, Grover PL, eds). Berlin:Springer-Verlag, KG, 1990:373-407.
443. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 16:39-52 (1995).
444. Colvin ME, Hatch FT, Felton JS. Chemical and biological factors affecting mutagen potency. Mutat Res 400:479-492 (1998).
445. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455 (1996).
446. Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 74:1-5 (1996).
447. Rao NM, Pai SA, Shinde SR, Ghosh SN. Reduced DNA repair capacity in breast cancer patients and unaffected individuals from breast cancer families. Cancer Genet Cytogenet 102:65-73 (1998).
448. Miki Y, Swensen J, Shattuckeidens D, Futreal PA, Harshman K, Tavtigian S, Liu QY, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71 (1994).
449. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792 (1995).
450. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins. FASEB J 11:68-76 (1997).
451. 2-M cell cycle control in human mammary epithelial cells. Cancer Res 57:3351-3355 (1997).
452. Scully R, Chen JJ, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425-435 (1997).
453. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-810 (1997).
454. WAF1/CIP1. Nature 389:187-190 (1997).
455. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell. Growth Differ 8:801-809 (1997).
456. Zhang HB, Somasundaram K, Peng Y, Tian H, Zhang HX, Bi DK, Weber BL, El-Deiry WS. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713-1721 (1998).
457. Zhang HB, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 92:433-436 (1998).
458. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645-1648 (1994).
459. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:5100-5103 (1993).
460. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059-5063 (1994).
461. Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, Ionov Y, Perucho M, Kunkel TA. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 269:14367-14370 (1994).
462. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair related to multiple skin cancers and drug use. Cancer Res 54:437-440 (1994).
463. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M. Yin S, Barrett JC, Kolodner RD, Kunkel TA. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55:6063-6070 (1995).
464. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55:2304-2309 (1995).
465. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5:382-395 (1995).
466. Pandita TK, Hittelman WN. Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck. Int J Cancer 61:738-743 (1995).
467. Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. Hum Mol Genet 5:1489-1494 (1996).
468. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 56:4103-4107 (1996).
469. Li D, Wang M, Cheng L, Spitz MR, Hittelman WN, Wei Q. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 56:3638-3641 (1996).
470. Chen WS, Chen JY, Liu JM, Lin WC, King KL, Whang Peng J, Yang WK. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer 74: 470-474 (1997).
471. Paz-y-Mino C, Penaherrera MS, Sanchez ME, Cordova A, Gutierrez S, Ocampo L, Leone PE. Comparative study of chromosome aberrations induced with aphidicolin in women affected by breast cancer and cervix uterine cancer. Cancer Genet Cytogenet. 94:120-124 (1997).
472. Wei Q. Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Fan Y, Bruner JM, Yung WK, Levin VA, Kyritsis AP. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 57:1673-1677 (1997).
473. Loeb LA. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res. 72:25-56 (1998).
474. Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 28:69-85 (1996).
475. Umar A, Kunkel TA. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 238:297-307 (1996).
476. Paulson TG, Wright FA, Parker BA, Russack V, Wahl GM. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 56:4021-4026 (1996).
477. 2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58:767-778 (1998).
478. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer Cell 82:321-330 (1995).
479. Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW, Wakeham A, Liu B, et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 11:64-70 (1995).
480. -/-; Min mice. Cancer Res 58:1087-1089 (1998).
481. Prolla TA, Baker SM, Harris AC, Tsao J-L, Yao X, Bronner CE, Zheng B, Gordon M, Reneker J, Amheim N, et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 18:276-279 (1998).
482. Jackson SP. The recognition of DNA damage. Curr Opin Genet Dev 6:19-25 (1996).
483. Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J 10:238-247 (1996).
484. Donehower LA. Genetic instability in animal tumorigenesis models. Cancer Surv 29:329-352 (1997).
485. Harley CB, Sherwood SW. Telomerase, checkpoints and cancer. Cancer Surv 29:263-284 (1997).
486. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells [see comments]. Proc Natl Acad Sci USA 94:2545-2550 (1997).
487. Kaufmann WK. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 217:327-334 (1998).
488. Heppner GH, Miller FR. The cellular basis of tumor progression. Int Rev Cytol 177:1-56 (1998).
489. Tennant RW. A perspective on nonmutagenic mechanisms in carcinogenesis. Environ Health Perspect 3:231-236 (1993).
490. Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. Salmonella mutagenicity tests. II: Results from the testing of 270 chemicals. Environ Mutagen 7:1-119 (1986).